GYS32661 (GYS 32661) is a potent Rac inhibitor capable of inhibiting both Rac1 and Rac1b, inhibited activated Rac1 with IC50 of 1.18 uM in in vitro pull-down assays.

​​BMS-986463​​ is a novel, first-in-class targeted protein degrader designed to specifically eliminate WEE1 kinase, a master regulator of cell cycle progression.

​​LRK-4189​​ represents a potential first-in-class oral small molecule degrader targeting the lipid kinase PIP4K2C, with therapeutic applications in microsatellite stable colorectal cancer and other solid tumors.

​​ETN029​​ represents an innovative macrocyclic peptide therapeutic specifically engineered to target the atypical Notch ligand DLL3. This target exhibits highly selective overexpression on the surface of small cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC) cells, though its relatively low expression density presents significant drug development challenges.

​​MOMA-341​​ is a highly selective covalent inhibitor targeting the Werner syndrome helicase (WRN) protein. Research has demonstrated that WRN plays an essential role in maintaining tumor cell viability in microsatellite instability-high (MSI-H) cancers, while being dispensable in normal tissues. This unique biological characteristic positions WRN inhibition as a promising therapeutic strategy that could selectively target cancer cells while minimizing effects on healthy tissues.

TYRA-200 represents a next-generation covalent inhibitor specifically engineered to target FGFR2, addressing critical limitations in current therapeutic options. The fibroblast growth factor receptor 2 plays pivotal roles in cellular proliferation and differentiation, with its genetic alterations strongly implicated in intrahepatic cholangiocarcinoma (iCCA) pathogenesis - particularly the FGFR2 fusions observed in 10-15% of iCCA cases. While pan-FGFR inhibitors have recently emerged as treatment options for advanced biliary tract cancers, their clinical utility is frequently compromised by polyclonal resistance mutations, predominantly within the FGFR2 kinase domain. TYRA-200 was developed through structure-guided rational design to overcome these resistance mechanisms.

Zolucatetide demonstrates potent inhibitory activity against β-catenin, exhibiting sub-50 nanomolar IC50 values in biochemical assays. This investigational compound mechanistically disrupts the protein-protein interaction between β-catenin and T-cell factor (TCF) transcription factors, thereby interfering with canonical Wnt signaling pathway activation. Preclinical studies have revealed its promising antitumor efficacy across multiple cancer models.

​​[11C]MK-7337​​ is an innovative positron emission tomography (PET) radioligand specifically designed for imaging α-synuclein pathology associated with Parkinson's disease. The neurodegenerative disorder is characterized by abnormal accumulation of α-synuclein protein aggregates, forming Lewy bodies in the brain. Early and precise detection of these pathological changes is crucial for timely intervention and disease progression management.

​​PF-07293893​​ represents a novel and selective activator targeting the AMPKγ3 isoform, developed as a potential therapeutic for heart failure. As a central regulator of cellular energy metabolism, AMPK plays a pivotal role in critical processes including fatty acid synthesis and mitochondrial biogenesis, making it an attractive target for various metabolic disorders.

​​AZD0233​​ is a novel small-molecule therapeutic agent targeting the chemokine receptor CX3CR1. This receptor is predominantly expressed on immune cells including monocytes, macrophages, natural killer (NK) cells, and memory effector T cells, where it specifically interacts with its sole ligand CX3CL1 (fractalkine).

PF-07899895 (designated as compound 34) demonstrates potent inhibitory activity against salt-inducible kinases (SIKs), exhibiting IC50 values of 1.2 nM for SIK1, 0.9 nM for SIK2, and 1.8 nM for SIK3.

BMS-986470​​ is an investigational drug designed to address the long-standing unmet medical needs in sickle cell disease (SCD). This condition is caused by mutations in the β-globin gene, leading to abnormal hemoglobin that polymerizes under hypoxic conditions, distorting red blood cells and triggering painful vaso-occlusive crises and hemolysis.

​​IID432​​ is a small-molecule drug candidate under development for the treatment of Chagas disease (American trypanosomiasis). This disease has long afflicted millions of patients worldwide, yet current therapies often suffer from prolonged treatment durations, inconsistent efficacy, and suboptimal safety profiles.

Onvansertib, also know as NMS-P937, PCM-075 and NMS1286937, is an oral Polo-like kinase 1 (PLK1) inhibitor, a key regulator of cell cycle progression and mitosis. It selectively inhibits PLK1 with a reported half-maximal inhibitory concentration (IC₅₀) of approximately 2 nM, while demonstrating significantly lower activity against other Polo-like kinases (PLK2 and PLK3). Onvansertib has shown potent anti-proliferative effects in various cancer cell lines, particularly in colorectal cancer, acute myeloid leukemia (AML), and prostate cancer models. It induces mitotic arrest, leading to apoptosis in tumor cells. Onvansertib has demonstrated synergistic effects when combined with chemotherapeutics such as irinotecan, 5-fluorouracil (5-FU), and decitabine, enhancing their efficacy in resistant cancers.

H-D-Phe-Pip-Arg-pNA (S-2238), a chromogenic substrate, is patterned after the N-terminal portion of the A alpha chain of fibrinogen, which is the natural substrate of thrombin. H-D-Phe-Pip-Arg-pNA is specific for thrombin and is used to measure antithrombin-heparin cofactor (AT-III). The AT-III assay using H-D-Phe-Pip-Arg-pNA is sensitive, accurate, and easy to perform.

DPyPE is a phosphatidylethanolamine lipid composed of polyisoprene alkyl chains. DPyPE is a co-lipid forvaxfectin mixed with GAP-DMORIE in a 1:1 ratio.

DMG-PEG-Mannose ,1,2-Dimyristoyl-sn-glycerol-methoxypolyethylene glycol-Mannose from kamulin.

Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.

Genz-644282 is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity(IC50=1.2 nM).

S.pombe lumazine synthase-IN-1 is an inhibitor of lumazine synthases with Ki values of 243 μM and 9.6 μM for Schizosaccharomyces pombe and Mycobacterium tuberculosis lumazine synthases, respectively.

18:0 mPEG2000 PE (DSPE-mPEG2000) is a PEG-based phospholipid. 18:0 mPEG2000 PE can be used to synthesis liposomes for delivering cancer agents.

DSPE-PEG-Streptavidin is an important biocoupling molecule widely used in biomedical research, especially in drug delivery, targeted therapies, immunodiagnostics and biosensors. Through the specific binding between streptavidin and biotin, DSPE-PEG-Streptavidin can help to achieve efficient loading and targeted action in targeted delivery systems. In addition, the molecule is widely used in molecular imaging and bioassays, especially for molecular recognition using the strong affinity between streptavidin and biotin in assay platforms that require high sensitivity and specificity.

F1957-0088 is a small molecule targeting the UHRF1 tandem Tudor domain (TTD) with TR-FRET (TTD vs. H3K9me3) EC50 of 45.1 uM.

IACS-17817 is a clinical-grade catalytic NSD2 inhibitor (NSD2i) with IC50 of about 19 nM. IACS-17817 shows highly selective for NSD2 over related lysine methyltransferases (KMTs), including NSD1 and NSD3.

IACS-17596 is a clinical-grade catalytic NSD2 inhibitor (NSD2i) with IC50 of about 8.8 nM.IACS-17596 shows highly selective for NSD2 over related lysine methyltransferases (KMTs), including NSD1 and NSD3

JBI-097 a dual LSD1/HDAC6 inhibitor with IC50 of 6 nM/48 nM. JBI-097 also shows strong modulation of HDAC6 and LSD1 specific biomarkers, alpha-tubulin, CD86, CD11b, and GFi1b. JBI-097 shows a stronger effect in erythroleukemia, multiple myeloma xenograft models, and in CT-26 syngeneic model.

ATPγS (tetralithium salt) is a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A.

Nav1.1 activator 1 (compound 4), a highly potent Nav1.1 activator with BBB penetration, increases decay time constant (tau) of Nav1.1 currents at 0.03 μM along with significant selectivity against Nav1.2, Nav1.5, and Nav1.6.

Lipid-87​​ is an ionizable lipid developed by Generation Bio, characterized by its ​​tertiary amine group​​ for pH-dependent protonation and ​​dual C16/C17 aliphatic chains​​ that enhance hydrophobic stability.As the core component (47.5–57.5 mol%) of stealth lipid nanoparticles (LNPs), Lipid87 enables extended blood circulation (>24-hour half-life vs. 30 min for conventional LNPs) by synergizing with steric-stabilizing polymers (e.g., DSG-PEG₂₀₀₀-OMe), achieves >95% encapsulation efficiency for mRNA/ceDNA with low cytotoxicity (IC₅₀ >100 μM), and drives liver-specific targeting (>80% hepatocyte transfection at 0.5 mpk), effectively restoring 40% FIX activity in hemophilia B models for over 7 days.

Difelikefalin (CR-845; FE-202845) is a peripherally restricted and selective agonist of kappa opioid receptor (KOR). Difelikefalin produces anti-inflammatory effects and has the potential in modulating pruritus in conditions such as chronic kidney disease[1][2].